Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation

References

• Chertkow H, Feldman HH, Jacova C, et al. Definitions of dementia and predementia states in Alzheimer’s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther. 2013;5(Suppl 1):S2.
   PubMed Web of Science ®Google Scholar
• Tan C-C, Yu J-T, Wang H-F, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimer’s Disease. 2014;41(2):615–631.
   PubMed Web of Science ®Google Scholar
• Ferreira-Vieira TH, Guimaraes IM, Silva FR, et al. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):101–115.
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science (New York, NY). 1982;215(4537):1237–1239.
   Google Scholar
• Lane RM, Darreh-Shori T. Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value. J Alzheimer’s Disease. 2015;44(4):1039–1062.
   PubMed Web of Science ®Google Scholar
• Colovic MB, Krstic DZ, Lazarevic-Pasti TD, et al. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315–335.
   PubMed Web of Science ®Google Scholar
• Tang E, Ravaud P, Riveros C, et al. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med. 2015;13:189.
   PubMed Web of Science ®Google Scholar
• Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer’s disease:: getting on and staying on. Curr Ther Res Clin Exp. 2003;64(4):216–235.
   PubMed Web of Science ®Google Scholar
• Prvulovic D, Schneider B. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer’s disease. Expert Opin Drug Metab Toxicol. 2014;10(7):1039–1050.
   PubMed Web of Science ®Google Scholar
• Sozio P, Cerasa LS, Marinelli L, et al. Transdermal donepezil on the treatment of Alzheimer’s disease. Neuropsychiatr Dis Treat. 2012;8:361–368.
   PubMed Web of Science ®Google Scholar
• Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2003;(3):Cd001190. DOI:10.1002/14651858.cd001190
   PubMedGoogle Scholar
• Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet (London, England). 2006;367(9516):1057–1065.
   PubMed Web of Science ®Google Scholar
• Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: A pooled analysis of three clinical trials. Curr Med Res Opin. 2009;25(11):2577–2587.
   PubMed Web of Science ®Google Scholar
• Nozawa M, Ichimiya Y, Nozawa E, et al. Clinical effects of high oral dose of donepezil for patients with Alzheimer’s disease in Japan. Psychogeriatrics. 2009;9(2):50–55.
   PubMed Web of Science ®Google Scholar
• Kim K-A, Lim JL, Kim C, et al. Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. Clin Ther. 2011;33(7):965–972.
   PubMed Web of Science ®Google Scholar
• Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73(10):761–767.
   PubMed Web of Science ®Google Scholar
• Blesa R, Bullock R, He Y, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer’s disease. Pharmacogenet Genomics. 2006;16(11):771–774.
   PubMed Web of Science ®Google Scholar
• Doody RS, Corey-Bloom J, Zhang R, et al. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer’s disease. Drugs Aging. 2008;25(2):163–174.
   PubMed Web of Science ®Google Scholar
• Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234–1251.
   PubMed Web of Science ®Google Scholar
• Farlow M, Veloso F, Moline M, et al. Safety and tolerability of donepezil 23 mg in moderate to severe alzheimer’s disease. BMC Neurol. 2011;11(57):1–8.
   PubMed Web of Science ®Google Scholar
• Christensen DD. Higher-dose (23 mg/day) Donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer’s disease. Postgrad Med. 2012;124(6):110–116.
   PubMed Web of Science ®Google Scholar
• Salloway S, Mintzer J, Cummings JL, et al. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease. Am J Alzheimer’s Dis Other Demen. 2012;27(6):421–432.
   PubMed Web of Science ®Google Scholar
• Han S-H, Lee J-H, Kim SY, et al. Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer’s disease. Acta Neurol Scand. 2017;135(2):252–256.
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Farlow MR, et al. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: A subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012;33(2–3):164–173.
   PubMed Web of Science ®Google Scholar
• Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006;21(5–6):353–363.
   PubMed Web of Science ®Google Scholar
• Haig GM, Pritchett Y, Meier A, et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer’s dementia. J Alzheimer’s Dis. 2014;42(3):959–971.
   PubMed Web of Science ®Google Scholar
• Gault LM, Ritchie CW, Robieson WZ, et al. A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer’s dementia. Alzheimer’s Dement. 2015;1(1):81–90.
   Google Scholar
• Gault LM, Lenz RA, Ritchie CW, et al. ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Alzheimer’s Res Ther. 2016;8(1):44.
   PubMed Web of Science ®Google Scholar
• Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69(5):459–469.
   PubMed Web of Science ®Google Scholar
• Marek GJ, Katz DA, Meier A, et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer’s disease. Alzheimer’s Dement. 2014;Part S. 10(5):S364–S73.
   Web of Science ®Google Scholar
• Zhang Z, Yu L, Gaudig M, et al. Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study. Neuropsychiatr Dis Treat. 2012;8:571–577.
   PubMed Web of Science ®Google Scholar
• Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer’s disease. Curr Med Res Opin. 2006;22(3):483–494.
   PubMed Web of Science ®Google Scholar
• Pakdaman H, Harandi AA, Hatamian H, et al. Effectiveness and safety of MLC601 in the treatment of mild to moderate Alzheimer’s disease: a multicenter, randomized controlled trial. Dement Geriatr Cogn Dis Extra. 2015;5(1):96–106.
   PubMed Web of Science ®Google Scholar
• Homma A, Atarashi H, Kubota N, et al. Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer’s disease: a randomized, double-blind trial. J Alzheimer’s Disease. 2016;52(1):345–357.
   PubMed Web of Science ®Google Scholar
• Eskander MF, Nagykery NG, Leung EY, et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer’s plaques and tangles. Brain Res. 2005;1060(1–2):144–152.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer’s dementia. Drugs Aging. 2014;31(8):639–649.
   PubMed Web of Science ®Google Scholar
• Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015;9:Cd001191.
   PubMedGoogle Scholar
• Cummings JL, Farlow MR, Meng X, et al. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer’s disease. Clin Drug Investig. 2010;30(1):41–49.
   PubMed Web of Science ®Google Scholar
• Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm(2)) in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(5):341–353.
   PubMed Web of Science ®Google Scholar
• Pregelj P. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer’s dementia in naturalistic conditions. Psychogeriatrics. 2012;12(3):165–171.
   PubMed Web of Science ®Google Scholar
• Seibert J, Tracik F, Articus K, et al. Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice. Neuropsychiatr Dis Treat. 2012;8:141–147.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc. 2007;55(10):1517–1523.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Robillard A, Cohen S, et al. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Curr Med Res Opin. 2013;29(8):989–1000.
   PubMed Web of Science ®Google Scholar
• Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin Pharmacol Ther. 2008;83(1):106–114.
   PubMed Web of Science ®Google Scholar
• Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383–1392.
   PubMed Web of Science ®Google Scholar
• Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;20(2–3):120–132.
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):Cd005593. DOI:10.1002/14651858.CD005593
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211–225.
   PubMed Web of Science ®Google Scholar
• Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer’s disease. Drugs Aging. 2015;32(7):537–547.
   PubMed Web of Science ®Google Scholar
• Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol. 2004;11(2):e274–e285.
   PubMedGoogle Scholar
• Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer’s disease: systematic review of the ‘real-world’ evidence. Dement Geriatr Cogn Disord. 2009;28(5):389–403.
   PubMed Web of Science ®Google Scholar
• Kroger E, Mouls M, Wilchesky M, et al. Adverse drug reactions reported with cholinesterase inhibitors: an analysis of 16 years of individual case safety reports from VigiBase. Ann Pharmacother. 2015;49(11):1197–1206.
   PubMed Web of Science ®Google Scholar
• Gustafsson M, Sandman PO, Karlsson S, et al. Association between behavioral and psychological symptoms and psychotropic drug use among old people with cognitive impairment living in geriatric care settings. Int Psychogeriatrics. 2013;25(9):1415–1423.
   PubMed Web of Science ®Google Scholar
• Ali TB, Schleret TR, Reilly BM, et al. Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada. PloS One. 2015;10(12):e0144337.
   PubMed Web of Science ®Google Scholar
• Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52(4):225–241.
   PubMed Web of Science ®Google Scholar
• Tavassoli N, Sommet A, Lapeyre-Mestre M, et al. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf. 2007;30(11):1063–1071.
   PubMed Web of Science ®Google Scholar
• Howes LG. Cardiovascular effects of drugs used to treat Alzheimer’s disease. Drug Saf. 2014;37(6):391–395.
   PubMed Web of Science ®Google Scholar
• Hernandez RK, Farwell W, Cantor MD, et al. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system. J Am Geriatr Soc. 2009;57(11):1997–2003.
   PubMed Web of Science ®Google Scholar
• Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9):867–873.
   PubMedGoogle Scholar
• Isik AT, Yildiz GB, Bozoglu E, et al. Cardiac safety of donepezil in elderly patients with Alzheimer disease. Intern Med. 2012;51(6):575–578.
   PubMed Web of Science ®Google Scholar
• Kim DH, Brown RT, Ding EL, et al. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019–1031.
   PubMed Web of Science ®Google Scholar
• Rowland JP, Rigby J, Harper AC, et al. Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psychiatr Treat. 2007;13(3):178–184.
   Google Scholar
• Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ (Clinical Research Ed). 1997;315(7115):1096–1099.
   PubMed Web of Science ®Google Scholar
• Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808–813.
   PubMedGoogle Scholar
• Lu C-J, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry. 2003;11(4):458–461.
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58(3):427–433.
   PubMed Web of Science ®Google Scholar
• Bidzan L, Bidzan M. Withdrawal syndrome after donepezil cessation in a patient with dementia. Neurol Sci. 2012;33(6):1459–1461.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther. 2013;5(Suppl 1):S5.
   PubMed Web of Science ®Google Scholar
• O’Regan J, Lanctot KL, Mazereeuw G, et al. Cholinesterase inhibitor discontinuation in patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015;76(11):e1424–e1431.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Nadel A, Masterman D, et al. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol. 2001;14(2):101–108.
   PubMed Web of Science ®Google Scholar
• Herrmann N, O’Regan J, Ruthirakuhan M, et al. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. J Am Med Dir Assoc. 2016;17(2):142–147.
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Herrmann N, LouLou MM. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease. J Psychiatry Neurosci. 2003;28(1):13–26.
   PubMed Web of Science ®Google Scholar